We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Did you mean my care
Information on the reporting, investigation and management of Neonatal Enteroviral Myocarditis (NEM).
Patient summary form for health professionals to report cases of Neonatal Enteroviral Myocarditis (NEM).
Information for healthcare professionals on myocarditis and pericarditis following COVID-19 vaccination.
What is generally known about myocarditis and pericarditis Myocarditis and…
Guidance relating to blood clotting, myocarditis and Guillain-Barré Syndrome (GBS) after COVID-19 vaccination.
Clinical guidance on myocarditis and pericarditis after COVID-19 vaccination for healthcare professionals.
The diagnosis, management and epidemiology of enterovirus infections.
Revisions have been made to the information for healthcare professionals and information for UK vaccine recipients for the COVID-19 Vaccine Moderna and Pfizer/BioNTech COVID-19 vaccine following a thorough review of extremely rare reports of myocarditis and pericarditis after COVID-19…
Information for health professionals on the epidemiology, transmission and prevention of Chlamydia abortus which can cause stillbirth or abortion in humans.
Documents relating to the new coronavirus (COVID-19) vaccination programme.
The epidemiology, symptoms, diagnosis and management of severe fever with thrombocytopaenia syndrome (SFTS).
Following a review of evidence by the Joint Committee on Vaccination and Immunisation (JCVI), advice on second doses for young people aged 16 to 17 was issued earlier this week.
Statement from the Joint Committee on Vaccination and Immunisation (JCVI) on COVID-19 vaccination of children and young people aged 5 to 11 years and booster vaccinations in those aged 12 to 17 years.
The Joint Committee on Vaccination and Immunisation (JCVI) is today advising that all 16 and 17 year olds receive their first dose of the Pfizer-BioNTech vaccine.
Advice from the Joint Committee on Vaccination and Immunisation (JCVI) on COVID-19 vaccination in children and young people aged 16 to 17 years.
JCVI has advised that, in addition to those aged over 50 years and at higher risk from coronavirus, all adults aged 40 to 49 years should be offered an mRNA booster.
A report covering adverse reactions to approved COVID-19 vaccines
Updated advice from the Joint Committee on Vaccination and Immunisation (JCVI) on vaccination of children aged 12 to 15.
Recent information relating to COVID-19 vaccines and medicines that has been published since the October 2022 issue of Drug Safety Update, up to 24 November 2022.
Statement setting out the advice from the Joint Committee on Vaccination and Immunisation (JCVI) on COVID-19 vaccination for children aged 6 months to 4 years.
The Joint Committee on Vaccination and Immunisation (JCVI) is today advising that children at increased risk of serious coronavirus (COVID-19) disease are offered a vaccine.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).